CRL Reinstated by UBS -- Price Target Announced at $357.00

gurufocus.com · 2026-09-30

Charles River Laboratories Analyst Rating Update On %B %d, %Y, Charles River Laboratories (CRL) has been reinstated by UBS with a "Buy" rating and a price ta

TickrTrends take: UBS has reinstated coverage of CRL with a price target of $357, which represents a specific analyst perspective on the stock's fair value. Given TickrTrends' current assessment that CRL is overvalued, investors focused on valuation metrics should monitor how the stock performs relative to both the UBS target and broader healthcare sector valuations. The reinstatement of analyst coverage may influence market sentiment, but valuation-oriented investors will want to track whether the stock moves toward or away from the TickrTrends overvalued assessment in coming periods.

Read the full story at gurufocus.com →